Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 5, 2016. The report announces the publication of results from the Salford Lung Study (SLS) in the New England Journal of Medicine (NEJM) and their presentation at the European Respiratory Society (ERS) International Congress. The study evaluates the effectiveness and safety of Relvar Ellipta (fluticasone furoate/vilanterol) in patients with chronic obstructive pulmonary disease (COPD) compared to usual care in a real-world clinical setting.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is a scientific and clinical update rather than a financial earnings report.
Material Changes and Clinical Results
The primary material change reported is the publication of clinical data demonstrating the efficacy of Relvar Ellipta:
- Exacerbation Reduction: In patients with a history of exacerbations, treatment with Relvar Ellipta resulted in a statistically significant 8.4% reduction in the rate of moderate or severe exacerbations compared to usual care (p=0.025).
- Subgroup Analysis: A similar 8.0% reduction was observed in patients already on an inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) regimen at baseline.
- Health Status: 45% of patients on Relvar Ellipta showed a clinically relevant improvement in their COPD Assessment Test (CAT) score, compared to 36% in the usual care group.
- Safety Profile: The incidence of serious adverse events was similar between groups (29% vs 27%). Pneumonia rates were non-inferior (7% vs 6%).
- Healthcare Utilization: While exacerbations decreased, there was a 12.3% increase in overall primary care contacts for patients on Relvar Ellipta.
Outlook, Risks, and Management Commentary
Management Commentary: GSK's Global Medical Head for Respiratory, Neil Barnes, stated the results provide robust evidence on how treatment choice influences patient outcomes. Innoviva's CEO, Michael W. Aguiar, noted the data confirms effectiveness against both usual care and other medicines in the same class.
Future Outlook: A second Salford Lung Study focusing on asthma is currently underway, with results expected in 2017.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers regarding risks that could cause actual results to differ from projections. Specific clinical risks for Relvar Ellipta (Breo Ellipta in the US) include:
- Increased risk of asthma-related death associated with long-acting beta2-agonists (LABA).
- Increased incidence of pneumonia, including fatal cases.
- Contraindications for acute bronchospasm relief and severe hypersensitivity.
- Potential for cardiovascular effects, bone mineral density decreases, and ocular issues.
Key Facts for Investor Verification
- Verify the commercial impact of the Salford Lung Study results on Relvar Ellipta/Breo Ellipta sales volumes and market share.
- Confirm the timeline and potential commercial value of the upcoming asthma-focused Salford Lung Study results expected in 2017.
- Review the royalty revenue implications for partner Innoviva Inc. based on the confirmed efficacy of the partnered respiratory assets.
- Monitor regulatory communications regarding the safety profile, specifically pneumonia risks, in light of the EMA's post-authorisation measures.
- Check subsequent quarterly financial reports for any revenue recognition or margin changes attributed to the respiratory franchise performance.